ELI LILLY AND COMPANY Operating Lease Cost
ELI LILLY AND COMPANY (LLY) reported Operating Lease Cost of $209.60 million for the 12-month period ending 2024-12-31, per its 10-K filed 2025-02-19.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingLeaseCost · last filed 2025-02-19
- ELI LILLY AND COMPANY operating lease, cost for the quarter ending 2019-12-31 was $68.50M.
- ELI LILLY AND COMPANY operating lease, cost for the quarter ending 2019-09-30 was $38.20M.
- ELI LILLY AND COMPANY operating lease, cost for the quarter ending 2019-06-30 was $34.00M.
- ELI LILLY AND COMPANY operating lease, cost for the quarter ending 2019-03-31 was $32.10M.
- ELI LILLY AND COMPANY operating lease, cost for fiscal 2024 was $209.60M, a 22.43% increase from fiscal 2023.
- ELI LILLY AND COMPANY operating lease, cost for fiscal 2023 was $171.20M, a 15.05% increase from fiscal 2022.
- ELI LILLY AND COMPANY operating lease, cost for fiscal 2022 was $148.80M, a 6.65% decline from fiscal 2021.
- ELI LILLY AND COMPANY operating lease, cost for fiscal 2021 was $159.40M, a 3.10% increase from fiscal 2020.
| Period end | Operating Lease, Cost 3 month | Operating Lease, Cost 6 month | Operating Lease, Cost 9 month | Operating Lease, Cost 12 month |
|---|---|---|---|---|
| 2024-12-31 | $209.60M 10-K · filed 2025-02-19 | |||
| 2023-12-31 | $171.20M 10-K · filed 2025-02-19 | |||
| 2022-12-31 | $148.80M 10-K · filed 2025-02-19 | |||
| 2021-12-31 | $159.40M 10-K · filed 2024-02-21 | |||
| 2020-12-31 | $154.60M 10-K · filed 2023-02-22 | |||
| 2019-12-31 | $68.50M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-23 | $106.70M derived: sum of 2 quarters · filed 2022-02-23 | $140.70M derived: sum of 3 quarters · filed 2022-02-23 | $172.80M 10-K · filed 2022-02-23 |
| 2019-09-30 | $38.20M 10-Q · filed 2019-10-25 | $72.20M derived: sum of 2 quarters · filed 2019-10-25 | $104.30M 10-Q · filed 2019-10-25 | |
| 2019-06-30 | $34.00M 10-Q · filed 2019-08-02 | $66.10M 10-Q · filed 2019-08-02 | ||
| 2019-03-31 | $32.10M 10-Q · filed 2019-05-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Akari Therapeutics Plc (AKTX) | $1,527.991B | -47,921.42 | |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| Merck & Co., Inc. (MRK) | United States | $365.215B | 99.96 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |